---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017302"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:27:06.746404+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q3 net loss $12.8M; IMM-1-104 IND cleared, trial recruiting; cash runway into Q3 2024

## Summary
- Net loss $12.8M ($0.49/share) vs $8.5M ($0.47) YoY; R&D $9.4M, G&A $3.8M.
- Cash and marketable securities $117.2M as of Sept 30, 2022, down from $150.2M at Dec 31, 2021.
- IND for IMM-1-104 cleared Sept 2022; Phase 1/2a trial recruiting, first patient expected Q4 2022.
- Preclinical data on IMM-6-415 presented at SITC; IND submission expected Q4 2023.
- FY 2022 GAAP operating expense guidance reduced to $53-56M from $55-60M; cash runway into Q3 2024.

## SEC filing metadata
- accession: 0001558370-22-017302
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000155837022017302/0001558370-22-017302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000155837022017302/imrx-20221110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017302
- JSON: https://secwatch.observer/filing/0001558370-22-017302.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017302.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported the third quarter ended September 30, 2022 results: net income $12.8 million, or $0.49 per share, EPS $0.49 per share. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2022
  - Net income: $12.8 million, or $0.49 per share
  - EPS: $0.49 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today reported financial results for the third quarter ended September 30, 2022, and provided recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000155837022017302/0001558370-22-017302-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.